GA-BIOLOG-ID
Biolog-id LLC, a developer and service provider of connected healthcare solutions, announced today its partnership with AirMed – one of the first air medical transport programs in the US. As part of this partnership, biolog-id’s cutting-edge technology will provide digital visibility to the inventory of red blood cells and liquid plasma across 5 locations in the state of Utah, covering one of the largest geographical areas in the nation, routinely transporting patients not only from Utah, but also from Colorado, Wyoming, Nevada, Montana, and Idaho.
Biolog-id’s blood components management platform will support the inventory replenishment of the different bases, as well as the traceability and documentation of the units selected by the teams at the AirMed bases.
“We are pleased to cooperate with the biolog-id team on the deployment of this technology across our operation,” said Cory Cox, AirMed Outreach Coordinator & Flight Paramedic at AirMed. “We are committed to delivering the highest quality of care to our patients and strive for excellence in every aspect of our profession. The cooperation with biolog-id perfectly aligns with this mission by ensuring the availability of some of the most critical life-saving tools we have at our disposal.”
“Cooperating with an inspiring organization like AirMed is a natural expansion of our current customer base of community donor center and hospital blood banks,” said Troy L. Hilsenroth, CEO biolog-id LLC. “As a former firefighter I am particularly excited about our technology supporting the important mission of the courageous men and women at AirMed.”
The biolog-id technology is compatible across multiple systems, software, and hardware. That flexibility of the biolog-id platform, coupled with a customer-centric innovation focus, facilitates the development of dedicated tools that address the changing conditions in the industry. With an expanding customer base in the US and worldwide, this combination drives the ability to efficiently configure biolog-id’s solution. While addressing the unique needs of both donor centers and hospital blood banks, this further enables our ability to effectively scale.
About biolog-id
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds. Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About ARUP Laboratories
ARUP Laboratories is a national nonprofit and academic reference laboratory at the forefront of diagnostic medicine. We are a CAP-, ISO 15189-, and CLIA-certified diagnostic lab with more than 35 years of experience supporting clients through unparalleled quality and service. Our forward-thinking community of academic experts and consultants are here to empower our clients with the most current industry knowledge and unparalleled guidance.
Company URL: https://www.aruplab.com/about
About U-Health AirMed:
AirMed was established on June 16, 1978, as the eighth air medical transport program in the nation. We fly trauma, burns, medical, pediatric, neonate, high-risk OB, and cardiac assist device patients 24 hours a day with six helicopters and two airplanes placed throughout northern Utah and Wyoming. We use the most state-of-the-art equipment available, which includes digital capnography, invasive line management, and intra-aortic balloon pumps for transport. We utilize cutting-edge airway technology including video laryngoscopy, advanced portable ventilators, and a variety of adjuncts for securing difficult or complex airways.
Company URL: https://healthcare.utah.edu/airmed/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005729/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Analysis Reveals 1 in 4 Refund Dollars Is Abusive; Introduces "Dynamic Returns," a New Policy Protect Feature, to Safeguard Revenue While Increasing Customer Satisfaction12.1.2026 14:00:00 CET | Press release
Riskified (NYSE: RSKD) a leader in ecommerce fraud and risk intelligence, today released a research analysis highlighting a growing customer experience dilemma: As merchants tighten controls to fight a surge in return and refund abuse, they are inadvertently creating a more restrictive and frustrating experience for their best customers. To help retailers mitigate this challenge, Riskified has introduced a new feature in its Policy Protect solution, Dynamic Returns, AI-powered return decisions that adapt in real-time based on customer eligibility. Riskified's 2024 analysis of over a million refund claims found that 1-2% of total order value measured in sales dollars was requested back as refunds, with nearly 1 in 4 dollars claimed being abusive. In response to rising abuse, many retailers are implementing restrictive tactics like flat return fees, shorter return windows, and delaying refunds, often taking 10+ days for warehouse inspection. These measures frustrate good customers, as 68
Esri’s Custom Chart Builder Adopted by the Shom (French Hydrographic and Oceanographic Office) for Nautical Chart Production12.1.2026 14:00:00 CET | Press release
Geospatial Solution for Safety-Critical Maritime Use Sets Global Benchmark for Chart Automation Esri, the global leader in location intelligence, announced today that the Shom (French Hydrographic and Oceanographic Office) has officially adopted Custom Chart Builder (CCB) for automated production of all paper nautical charts. Following extensive testing and configuration, Shom confirmed that CCB-generated charts meet the stringent safety standards required by the French Navy, marking a pivotal advancement in automating maritime cartography and reinforcing its role as a pioneer in maritime digital transformation. “This adoption demonstrates that high-quality, regulation-compliant paper charts can now be produced without manual intervention, dramatically reducing production time and cost,” said Rafael Ponce, Esri principal maritime consultant. “Shom’s endorsement validates Esri’s CCB as a trusted solution for hydrographic offices worldwide, supporting the transition to digital-first work
Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands12.1.2026 13:30:00 CET | Press release
Cellares’ new IDMO Smart Factory in Leiden, Netherlands, expands commercial-scale manufacturing capacity for European cell therapy patient populations through a standardized, automated, and highly scalable facility model Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commercieel Vastgoed. The facility will serve as Cellares’ European headquarters and expand the company’s global manufacturing network with dedicated regional capacity. Cell therapy manufacturing is patient-specific and time-sensitive, making regional production capacity increasingly important as programs advance from clinical development toward commercial supply. The new Netherlands hub is designed to provide European drug developers with access to automated manufacturing infrastructure, while maintaining alignment to a common production stan
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas12.1.2026 13:30:00 CET | Press release
Updated national AAC protocol supports hospital-based, fully-reimbursed compassionate access across three solid tumor settings Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France’s National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national treatment protocol for botensilimab (BOT) plus balstilimab (BAL) under France’s Autorisation d’Accès Compassionnel (AAC) framework. The updated protocol expands France’s previously granted AAC authorization for BOT+BAL in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases to eligible patients with certain ovarian cancers and soft-tissue sarcomas—diseases with substantial unmet medical need after standard options have been exhausted. The revised protocol is designed to broaden the eligibility criteria, allowing more patients with advanced solid tumors to have early access to BOT+BAL under reimbursed compassionate
Lilac and Traxys Announce Binding 10-Year Offtake Agreement for Great Salt Lake Lithium Production12.1.2026 13:00:00 CET | Press release
Definitive agreement secures 100% of Phase 1 production, advancing project toward final investment decision Lilac Solutions, a leading provider of direct lithium extraction technology, and Traxys North America, a leading global physical trader and merchant in metals and natural resources, today announced a binding 10-year offtake agreement for lithium carbonate produced at Lilac's Great Salt Lake facility in Utah. The agreement represents a major milestone in advancing the project toward construction and establishes a clear commercial pathway for one of the nearest-term domestic lithium projects in the United States. Under the terms of the definitive agreement, Traxys will purchase 50,000 tonnes of lithium carbonate over a 10-year period, representing 100% of the planned Phase 1 production capacity. The agreement is take-or-pay, with agreed pricing mechanisms linked to market indices. The Great Salt Lake Phase 1 facility is designed to produce 5,000 tonnes per annum of battery-grade li
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom